| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kary Eldred is Director at GALT. Kary Eldred's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $220K at current prices.
Our model assigns Kary Eldred a strong insider score of 81/100, based on 9 past trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +47.9%.
Net of sales, the GALT filings show accumulation of 26,500 shares.
Kary Eldred has 22 Form 4 filings on record from May 2018 to February 2026, all as Director at Galectin Therapeutics (GALT), 2018–2026.
The 24 reported transactions were 14 open-market purchases and 10 option or other derivative awards.
Counted by filing, the open-market trades come to 13 purchases worth about $54K and no sales.
The largest open-market purchase was 3,033 shares of GALT at an average $4.28 on May 31, 2019, about $13K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | GALT Galectin Therapeutics Inc. | Director | Buy | 300 | $2.70 | $810.00 | +0.5% | -24.6% | - | |
| Dec 23, 2025 | GALT Galectin Therapeutics Inc | Director | Buy10b5-1 | 700 | $3.73 | $2,611.00 | +1.1% | -28.3% | - | |
| Dec 23, 2025 | GALT Galectin Therapeutics Inc | Director | Buy | 700 | $3.73 | $2,611.00 | +1.1% | -28.3% | - | |
| Jul 21, 2025 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $2.93 | $2,925.00 | +1.6% | +85.8% | +40.5% | |
| Dec 24, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 13,469 | $0.82 | $11,044.58 | +26.8% | +96.3% | +379.4% | |
| Oct 23, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 500 | $2.60 | $1,300.00 | +1.0% | -52.3% | +98.8% | |
| Jan 16, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 400 | $2.39 | $956.00 | +0.8% | +114.8% | -29.7% | |
| Jan 16, 2024 | GALT Galectin Therapeutics Inc | Director | Buy | 500 | $1.79 | $892.90 | +1.0% | +114.8% | -29.7% | |
| Jul 19, 2023 | GALT Galectin Therapeutics Inc | Director | Buy | 1,598 | $1.79 | $2,854.03 | +3.4% | +22.8% | +46.8% | |
| Feb 21, 2023 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $1.59 | $1,591.10 | +2.2% | +13.7% | +16.3% |